EGFR and lung carcinoma: According to the trials LUX-lung 3 and LUX-Lung 6, afatinib outperformed traditional chemotherapy in stage IIIB or IV (7th edition of TNM) lung cancer adenocarcinoma with del19 EGFR mutation (pemetrexed-cisplatin in LUX-Lung 3 and gemcitabine-cisplatin in LUX-Lung 6, respectively).